Genetown
Filter News
Found 76,060 articles
-
BioSpace Hotbed maps have been a life sciences industry staple for over 30 years. Today the program features eight regional Hotbed Maps and the NextGen Bio Map which highlights some of the industry’s most promising startups.
-
Kymera Therapeutics Strengthens Leadership Team with the Appointment of Vijay Sabesan as Senior Vice President, Technical Operations
12/6/2021
Kymera Therapeutics, Inc. today announced the appointment of Vijay Sabesan as Senior Vice President, Technical Operations.
-
Nabla Bio Closes $11M Seed Financing led by Khosla Ventures and Zetta Venture Partners
12/6/2021
Nabla Bio, a next-generation antibody design company, announced the closing of a $11M Seed financing round.
-
Goldfinch Bio Strengthens Leadership Team with Appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer
12/6/2021
Goldfinch Bio today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO).
-
Arrakis Therapeutics Appoints James Mutamba, PhD, as Chief Business Officer
12/6/2021
Arrakis Therapeutics today announced that James Mutamba, PhD, has joined the company as Chief Business Officer.
-
Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA® Blood Test Since Its Launch A Year Ago
12/6/2021
Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA ® Blood Test Since Its Launch A Year Ago.
-
PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States
12/6/2021
PharmaEssentia’s BESREMi ® (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States.
-
Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer
12/6/2021
Axcella Therapeutics today announced that Margaret Koziel, M.D., has been promoted to the role of Chief Medical Officer and added as a member of the company’s executive team.
-
Decibel Therapeutics Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board
12/6/2021
Decibel Therapeutics today announced the appointments of Alison Finger, MBA and Saraswathy (“Sara”) Nochur, Ph.D. to its Board of Directors.
-
Kaleido Biosciences Announces Expansion of Collaboration with Janssen to Explore Potential of Microbiome Metabolic Therapies (MMT™) to Prevent Childhood-Onset of Atopic, Immune and Metabolic Conditions
12/6/2021
Kaleido Biosciences, Inc. today announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. (“Janssen”).
-
Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®
12/6/2021
Biofrontera Inc. (Nasdaq: BFRI), announced today that the first subject has been enrolled in a Phase 1 study to evaluate the safety and tolerability of photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) using three tubes of Ameluz® together with the company’s BF-RhodoLED® XL lamp.
-
Applied BioMath, LLC Announces Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
12/6/2021
Applied BioMath (www.appliedbiomath.com), today announced their collaboration with Celsius Therapeutics for the development of a semi-mechanistic pharmacokinetic / receptor occupancy model of a monoclonal antibody for the treatment of inflammatory bowel disease (IBD).
-
Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy
12/6/2021
Adicet Bio, Inc. (Nasdaq: ACET), today announced positive interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001, Adicet’s investigational therapy targeting CD20 for the potential treatment of B-cell Non-Hodgkin’s Lymphoma.
-
Karyopharm Announces Dosing of First Patient in a New Phase 2 Study Evaluating Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis
12/6/2021
Karyopharm Therapeutics Inc. today announced dosing of the first patient in a new Phase 2 study evaluating oral selinexor, the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, as a monotherapy versus physician's choice in patients with myelofibrosis (MF) previously treated with a JAK 1/2 inhibitor (XPORT-MF-035; NCT04562870).
-
NanoMosaic Closes a $40.75MM Over-Subscribed Series A Round
12/6/2021
NanoMosaic Inc. announced today that it has closed an oversubscribed $40,750,000 Series A round of financing led by RA Capital Management, joined by Insight Partners, Pura Vida Investments, Time BioVentures and Tiger Gene.
-
Fulcrum Therapeutics® Announces Additional HBG mRNA Induction from Higher Dose Cohorts in Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease and New Preclinical Mechanism Data
12/6/2021
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced positive results from the 20mg and 30mg dose cohorts in healthy adult volunteers in its Phase 1 clinical trial of FTX-6058.
-
New Study Shows Multiple Inflammasomes Combine to Cause Lupus, Macular Degeneration and Other Neuroinflammatory Diseases Such as Alzheimer’s Disease and Multiple Sclerosis
12/6/2021
Inflammasome Therapeutics (https://inflam.com), said today that research published in Science Immunology (https://www.science.org/doi/10.1126/sciimmunol.abi4493) “DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs”, uncovers a previously unrecognized mechanism by which NLRC4 combines with NLRP3 to form activated inflammasomes that trigger causes of active disease in macular degeneration and lupus.
-
Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Disease
12/6/2021
Ocular Therapeutix, Inc. today announced positive topline results from its Phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease.
-
Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast Cancer Symposium
12/6/2021
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma), today announced that it will host an investor event on updated data from the ongoing MARIO-3 clinical study during the San Antonio Breast Cancer Symposium.
-
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
12/6/2021
Merus N.V. today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually.